Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

20.0%

1 terminated out of 5 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

5Total
P 1 (1)
P 2 (3)
P 3 (1)

Trial Status

Not Yet Recruiting2
Recruiting2
Terminated1

Clinical Trials (5)

Showing 5 of 5 trials
NCT06708897Phase 1RecruitingPrimary

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

NCT07342478Phase 3RecruitingPrimary

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

NCT07459608Phase 2Not Yet Recruiting

Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma

NCT07682415Phase 2Not Yet RecruitingPrimary

Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0

NCT00714259Phase 2Terminated

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Showing all 5 trials

Research Network

Activity Timeline